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Immune checkpoint inhibition has transformed cancer treatment. For gastroesophageal
cancer, this class of drugs have demonstrated durable responses and survival
benefit in a subgroup of patients, resulting in regulatory approval. However, several
recent randomized phase III studies in gastroesophageal cancer have reported
negative results, blunting initial enthusiasm. Identification and validation of predictive
biomarkers with appropriate patient selection for benefit from immunotherapy is an
area of intense research with novel concepts rapidly emerging. In this review we
describe the latest immune checkpoint inhibitor trials which have been reported in
gastroesophageal cancers with a focus on predictive biomarkers. We also explore
novel biomarkers being developed to improve precision oncology for immunotherapy
in gastroesophageal cancers.
Keywords: immunotherapy, biomarker, gastric cancer, esophageal cancer, gastroesophageal cancer, immune
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INTRODUCTION
Gastroesophageal cancers (GEC) are a leading cause of cancer morbidity and mortality globally.
GEC may be classified as gastric cancer (GC) and esophageal cancer (EC) based on anatomical
location. GC is the third most common cause of cancer-related death, while EC is sixth (1).
Approximately 1.3 million patients die from GEC annually (GLOBOCAN database). Esophageal
cancers are further subtyped by histology into esophageal adenocarcinoma (EAC) and esophageal
squamous cell cancer (ESCC) (2). Management of GEC has evolved over time, with early clinical
trials of chemotherapy and radiation therapy combining both GC and EC (EAC and ESCC) in the
same trials (3). However, contemporary trials with newer agents are designed with more specific
inclusion criteria for GC or ESCC only (4).
GC is characterized by inter and intra-tumoral heterogeneity, leading to significant hurdles in
the advance of precision oncology in this tumor type (5). Chemotherapy remains the standard
of care (SOC) for metastatic GC. Although treatment regimens differ between regions and
institutes, platinum and 5-fluoropyrimidine (5FU) combination regimens are generally preferred in
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first-line treatment (6). Median overall survival in contemporary
clinical trials for platinum/5FU is 11 months (7). Multiple
targeted therapy phase III trials have failed for drugs targeting
EGFR, VEGF and PARP (8–11). Trastuzumab was one of the first
targeted therapies that received Food and Drug Administration
(FDA) approval in combination with cytotoxic chemotherapy for
a biomarker selected population (HER2 positive) in GC (12).
HER2 remains one of the few biomarkers of clinical value for the
treatment of metastatic GC. The Cancer Genome Atlas (TCGA)
classifies GC into four main subgroups—chromosomally instable
(CIN), genomically stable (GS), high microsatellite instability
(MSI), and Epstein-Barr virus (EBV) positive tumors (13).
However, until the recent emergence of immunotherapy, this
classification has not been incorporated into clinical practice.
Precision oncology in metastatic EC has also made slow
progress, with few in-roads for targeted therapy agents. The
TCGA classification of EC describe genetic and epigenetic
differences between EAC and ESCC (2). Epigenetically, EAC
resembles the CIN subtype of GC. The incidence of EBV and
MSI is extremely low in EC (<1%) (14). There are no targeted
therapies approved for the treatment of metastatic EC. Before the
immunotherapy era, all patients with metastatic EC were treated
with chemotherapy, with no predictive biomarkers to guide
treatment. However, contemporary trials in EC have integrated
biomarker discovery and validation, particularly those involving
immunotherapy (15).
Pathways that regulate the immune system are called immune
checkpoints. These pathways have evolved due to the biological
necessity of self-tolerance. However, several cancers coopt
immune checkpoints as a mechanism of immune-editing and
immune-evasion (16). The dependence of cancer on these
pathways can be therapeutically exploited, by targeting specific
checkpoints [immune checkpoint inhibitors (ICI)]. CTLA-4 is a
receptor expressed on regulatory T-cells (Tregs). It functions as a
negative co-stimulator, when bound to CD80 or CD86 on antigen
presenting cells, leading to modulation of immune response
(17). Ipilimumab is an anti-CTLA4 monoclonal antibody, and
is the first ICI to gain regulatory approval in cancer therapy
(for the treatment of melanoma) (18). Programmed cell death
1 (PD-1) is another negative co-stimulatory transmembrane
protein expressed on T-cells, B-cells, and NK cells. PD-1 binds
to PD-1 ligand (PD-L1) and PD-L2. PD-L1 is expressed on
tumor cells and multiple tissue types (19). The interaction
between PD-1 and PD-L1/2 promotes peripheral T effector
cell modulation, inhibits tumor cell apoptosis, and increases
conversion of T effector cells to Treg cells (17). Blockade
of the PD-1 axis with anti-PD-1 or anti-PD-L1 monoclonal
antibodies restores anti-tumor immune responses and leads to
tumor regression. Several anti-PD-1 and anti-PD-L1 antibodies
are now approved as single-agents and in combination with
other drugs for the treatment of multiple tumor types including
lung cancer, melanoma, renal cell carcinoma, hepatocellular
carcinoma, and others (20, 21). In GEC, the anti-PD-1 antibodies
pembrolizumab and nivolumab have demonstrated survival
benefit and gained regulatory approval. However, recently,
several phase III trials across multiple tumor types (including
GEC) have reported negative outcomes, with ICI failing to
demonstrate superiority over standard-of-care (SOC) therapies
(22–28). These studies highlight the importance of biomarker
development and appropriate patient selection for ICI.
In this review we first summarize the major immunotherapy
trials in GEC, including randomized phase III trials and major
phase II trials (leading to registration) reported before January
2020. Next, we focus on biomarkers that have been studied within
these trials, and finally we highlight emerging novel predictive
biomarkers of immunotherapy benefit in GEC.
PD-L1 IMMUNOHISTOCHEMISTRY
The measurement of intra-tumoral PD-L1 expression using
immunohistochemistry (IHC) is one of the earliest biomarkers
developed for predicting benefit from ICI (29). A method of
scoring PD-L1 called the tumor proportion score (TPS) was
developed for lung cancer, involved measurement of PD-L1
expression only within the tumor cells (30). The TPS score was
presented as the ratio of the number of PD-L1–expressing tumor
cells to all tumor cells present. The TPS method was found to
be inadequate in GEC, and it was found that measuring the
expression of PD-L1 in the immune cells surrounding the tumor
was especially important in GEC (31). The combined positive
score (CPS) was developed to consider the expression of PD-L1
on tumor cells and immune cells combined. CPS is the ratio of the
number of all PD-L1–expressing cells (tumor cells, lymphocytes,
macrophages) to the number of all tumor cells (32) (Figure 1).
The PD-L1 CPS score was developed using the 22C3 assay as a
companion diagnostic for pembrolizumab in GC and has been
FDA approved (33).
KEY TRIALS OF IMMUNE CHECKPOINT
INHIBITION IN GASTROESOPHAGEAL
CANCERS
Early data for ICI in GEC came from large basket studies of
pembrolizumab that included various advanced, solid tumors
expressing PD-L1. In the phase 1b KEYNOTE-012, 39 patients
with metastatic GC were included, and achieved an objective
response rate (ORR) of 22%, with a median duration of response
of 40 weeks (31). The phase 1b KEYNOTE-028 included 28
patients with metastatic EC. Both EAC and ESCC were included
and an ORR of 30% was achieved, with a median duration of
response of 15 months (34). These encouraging early results led
to larger, tumor-type specific single-arm phase II and randomized
phase III trials.
Metastatic Third-Line Gastric Cancer
ATTRACTION-2 (Nivolumab)
ATTRACTION-2 was a randomized phase III study run in Japan,
South Korea, and Taiwan (35). Patients with metastatic GC
that had progressed on at least 2 prior lines of therapy were
eligible for the study. In total 493 patients were randomized to
intravenous (i.v.) nivolumab 3 mg/kg every 2 weeks vs. placebo.
Nivolumab demonstrated an overall survival (OS) benefit of
5.3 months compared to 4.1 months for placebo (Table 1).
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FIGURE 1 | Multiplex immunohistochemistry/ immunofluorescence (mIHC/IF) staining of gastric carcinoma. Two gastric cancer samples are labeled with PD-L1 (Clone
22C3) (red), EpCAM (green), and DAPI (blue) by using mIHC/IF. EpCAM is a cell surface protein commonly expressed in gastric cancer cells. DAPI is a nuclear
counterstain. (A–C) PD-L1 staining (in red) can be observed only on the immune cells surrounding the tumor nests. There is minimal PD-L1 expression within the
tumor cells. Image A is mIHC/IF imaging of PD-L1 + DAPI, Image B is EpCAM + DAPI and Image C is PD-L1 + EpCAM + DAPI. (D–F) PD-L1 staining (in red) can be
seen in both tumor compartment (majority of the positive cells are located in the yellow highlighted box) and surrounding immune cells. Image D is mIHC/IF imaging of
PD-L1 + DAPI, Image E is EpCAM + DAPI and Image F is PD-L1 + EpCAM + DAPI. These images highlight the importance of considering immune-cell expression
along with tumor expression of PD-L1 IHC, and the differences between TPS and CPS scores in gastric cancer. Representative images are shown with HALOTM
pathology analysis software. (Magnification: 200X).
TABLE 1 | Key 3rd line trials for metastatic gastric cancer.
Name of trial ICI Comp N OS (months) PFS (months) ORR (%) References
ICI Comp HR ICI Comp HR ICI Comp
ATTRACTION-2 Nivo Placebo 493 5.3 4.1 0.6 1.6 1.4 0.6 11 0 (35)
KEYNOTE-059 Pembro NA 259 5.6 NA NA 2.0 NA NA 12 NA (36)
JAVELIN 300 Avel Pacli or Irino 371 4.6 5.0 1.1 1.4 2.7 1.7 2 4 (23)
ICI, immune checkpoint inhibitor; Comp, comparator arm; N, number of patients enrolled in the study; ORR, objective response rate; nivo, nivolumab; pembro, pembrolizumab; pacli,
paclitaxel; avel, avelumab; irino, irinotecan.
More importantly, there was a group of patients with refractory
disease that appeared to have durable benefit from treatment,
with 1-year and 2-year OS being superior in the nivolumab
arm [27 vs. 12% (1-year OS); 11 vs. 3% (2-year OS)] (37).
This trial led to the approval of nivolumab in the third-line
metastatic GC in Japan and Korea. The study was conducted in
a purely Asian population, raising the concern of applicability
in other populations. GC in Asian patients have been shown
to have a significantly different immune signature compared to
GC in non-Asian populations, with enrichment in Tregs (38).
Fortunately, results from trials including predominantly non-
Asian populations addressed these questions.
KEYNOTE-059—Cohort 1 (Pembrolizumab)
KEYNOTE-059 was a multi-cohort study of patients with
metastatic GC treated with pembrolizumab. Cohort 1 included
patients with metastatic GC that had progressed on at least 2
prior lines of therapy, and were treated with i.v. pembrolizumab
200mg (flat dose) every 3 weeks. This was a single-arm cohort
with all patients treated with pembrolizumab, conducted in 16
countries across the globe (36). Of the 259 patients enrolled,
objective response rate (ORR) was 12% and median OS was 5.6
months (Table 1). The results from this study led to the FDA
approval of pembrolizumab for third-linemetastatic GC. Patients
in the KEYNOTE-059 Cohort 1 were predominantly non-Asian
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(>80%). With similar ORR, median PFS and OS in KEYNOTE-
059 and ATTRACTION-2 (Table 1), concerns in the differential
responses to immunotherapy between Asian and non-Asian GC
populations were mitigated.
JAVELIN 300 Gastric Cancer (Avelumab)
JAVELIN 300 was a randomized phase III trial run globally, for
metastatic GC patients who had failed at least 2 prior lines of
systemic therapy (23). Patients were randomized to i.v. avelumab
(an anti-PD-L1 monoclonal antibody) 10 mg/kg every 2 weeks
or physicians’ choice of chemotherapy (paclitaxel or irinotecan).
The study randomized 371 patients, and failed to achieve its
primary endpoint of OS. There was no difference in OS between
avelumab or chemotherapy (4.6 vs. 5.0 months) (Table 1). PFS
was better in the chemotherapy arm, compared to avelumab [2.7
vs. 1.4 months, hazards ratio (HR)= 1.73].
The results from these third-line studies have led to the
incorporation of pembrolizumab and nivolumab into routine
clinical practice for GC. It is interesting to note the control
chemotherapy arm in the “negative” JAVELIN study had a
numerically higher PFS, and similar OS compared to nivolumab
in the “positive” ATTRACTION-2 study. This highlights
the importance of an appropriate control arm in designing
clinical trials.
Metastatic Third-Line Esophageal Cancer
KEYNOTE-180 (Pembrolizumab)
KEYNOTE-180 was a single-arm study of metastatic EC, that
had been treated with at least 2 prior lines of systemic therapy
(39). In total 121 patients were treated with pembrolizumab (63
with ESCC and 58 with EAC). ORR was 14% for ESCC and
5% for EAC. Median PFS was 2.0 months and median OS was
5.8 months.
Metastatic Second-Line Gastric Cancer
KEYNOTE-061 (Pembrolizumab)
KEYNOTE-61 was a randomized phase III study of
pembrolizumab against weekly paclitaxel for patients that
had progressed on 1 prior line of chemotherapy containing
a platinum and 5-fluouracil (5-FU) doublet (25). The study
randomized 592 patients in total, with the first 489 patients (83%)
being enrolled regardless of PD-L1 status. An interim review
by an independent data-monitoring committee recommended
that the enrollment for the remaining patients were restricted
to tumors with a PD-L1 combined positive score (CPS) of 1 or
more, based on poorer outcomes of patients with a CPS of 0 with
pembrolizumab. The study failed to demonstrate a statistically
significant survival difference between pembrolizumab and
paclitaxel chemotherapy. Median OS was 9.1 months for
pembrolizumab vs. 8.3 months for paclitaxel. Progression free
survival (PFS) was 1.5 vs. 4.1 months, in favor of paclitaxel. The
study however, had an interesting phenomenon of the survival
curves crossing between the two arms of the trial (for OS and
PFS at ∼8 to 10 months). The crossing of the survival curves
violates the assumption of proportional hazards and does not
yield a meaningful analysis using Cox regression (40). A small
proportion of patients have a prolonged and durable benefit from
pembrolizumab, with the survival curve reaching a plateau at 20
months (not observed in the chemotherapy arm). However, a
larger proportion of patients received third-line treatment in the
paclitaxel arm compared to pembrolizumab (58 vs. 46%). This
highlights the importance of disease control with chemotherapy
preventing rapid deterioration of function and performance
status precluding further lines of treatment. Identification
of a negative predictive biomarker of immunotherapy could
potentially help these patients avoid ineffective therapy.
Metastatic Second-Line Esophageal
Cancer
KEYNOTE-181 (Pembrolizumab)
The KEYNOTE-181 study was restricted to EC patients
only, included both EAC and ESCC as well as Siewart’s
type I gastroesophageal junction (GEJ) tumors (15). Patients
that had progressed on one prior line of the chemotherapy
were randomized to pembrolizumab or physician’s choice of
chemotherapy (paclitaxel, docetaxel or irinotecan). The study
was designed with three co-primary endpoints: OS in a) patients
with a PD-L1 CPS ≥ 10; b) patients with ESCC; c) patients in
the intention to treat (ITT), entire trial population. The study
randomized 628 patients and met only one of the three primary
endpoints (PD-L1 CPS ≥ 10 subgroup). In the ITT population,
there was no difference in survival between pembrolizumab and
chemotherapy (median OS 7.1 months in both arms) (Table 2).
Similarly, there was no statistically significant difference in
survival in the ESCC subpopulation (8.2 vs. 7.1 months). In
the CPS ≥ 10 subgroup, pembrolizumab had a significant
improvement in OS over paclitaxel (9.3 vs. 6.7 months). On the
basis of these results, pembrolizumab was granted FDA approval
for EC with CPS ≥ 10.
ATTRACTION-3 (Nivolumab)
This study was specific only for ESCC, and randomized 419
patients to nivolumab or physicians choice of paclitaxel or
docetaxel in the second-line (41). The study achieved its primary
endpoint, demonstrating a statistically significant improvement
in OS for nivolumab over chemotherapy (10.9 vs. 8.4 months).
The improvement in OS was found despite no difference in
PFS or ORR between nivolumab and chemotherapy (Table 2).
Prespecified analysis of health-related quality of life was better for
nivolumab compared to chemotherapy, which is of importance
given a proportion of patients continue with nivolumab for a
prolonged period of time (42).
The results of these second line studies have resulted in the
incorporation of pembrolizumab and nivolumab into routine
clinical practice for EC.
Metastatic Gastric Cancer First-Line
KEYNOTE-059—Cohort 2 and 3 (Pembrolizumab)
KEYNOTE-059 was a multi-cohort study for metastatic GC,
treated with pembrolizumab. Cohort 2 was a single-arm
cohort for first-line metastatic GC, treating patients with i.v.
pembrolizumab 200mg every 3 weeks, in combination with
cisplatin and infusional 5-FU or capecitabine (43). This cohort
included 25 patients, ORR was 60%, median PFS was 6.6 months,
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TABLE 2 | Key 2rd line trials for metastatic esophageal cancer.
Name of trial ICI Comp N OS (months) PFS (months) ORR (%) References
ICI Comp HR ICI Comp HR ICI Comp
ATTRACTION-3 Nivo Pacli or Doce 419 10.9 8.4 0.77 1.7 3.4 1.1 19 22 (41)
KEYNOTE-181 Pembro Pacli or Doce or Irino 628 7.1 7.1 0.89 2.1 3.4 1.1 13 7 (15)
ICI, immune checkpoint inhibitor; Comp, comparator; N, number of patients enrolled in the study; ORR, objective response rate; nivo, nivolumab; pembro, pembrolizumab; pacli,
paclitaxel; doce, docetaxel; irino, irinotecan.
and median OS was 13.8 months. Cohort 3 was a single-arm
cohort including patients with untreated metastatic GC, and a
PD-L1 CPS ≥ 1. Patients were treated with i.v. pembrolizumab
200mg every 3 weeks. In this cohort (n = 31) of single agent
pembrolizumab, ORR was 26%, median PFS was 3.3 months and
median OS was 20.7 months.
KEYNOTE-062 (Pembrolizumab)
KEYNOTE-062 was a three arm randomized phase III study
with multiple co-primary end- points conducted globally for
patients with untreated metastatic GC (28). In total, 763
patients were randomized into 3 arms: pembrolizumab single-
agent, chemotherapy (5-FU + platinum doublet) alone, and
pembrolizumab + chemotherapy. Based on the KEYNOTE-
061 data, this study was designed to only include PD-L1 CPS
≥ 1 population. Key co-primary end-points included non-
inferiority of pembrolizumab single-agent to chemotherapy for
OS, and superiority of pembrolizumab + chemotherapy over
chemotherapy alone for OS. Similar to other KEYNOTE studies,
multiple co-primary endpoint testing required α splitting and
stringent p-values to achieve the primary endpoints. The study
achieved one of its co-primary endpoints: pembrolizumab was
found to be non-inferior to chemotherapy (median OS 10.6
vs. 11.1 months, HR 0.91). Like KEYNOTE-061, there was a
“crossing of the curves” seen at 12 months. One-year OS for
pembrolizumab vs. chemotherapy was 47 vs. 46%, while 2-
year OS was 27 vs. 19%. The study failed to meet several
other primary endpoints. PFS of pembrolizumab was inferior
to chemotherapy (2.0 vs. 6.4 months, HR 1.66). ORR was also
inferior for pembrolizumab (15 vs. 37%). Pembrolizumab +
chemotherapy was not superior to chemotherapy alone (median
OS 12.5 vs. 11.1 months, HR 0.85). Interestingly, the 2-year OS of
the pembrolizumab+ chemotherapy arm was numerically lower
than the single agent-pembrolizumab arm (24 vs. 27%).
JAVELIN Gastric 100 (Avelumab)
The JAVELIN Gastric 100 study was a randomized phase III
trial of avelumab administered as switch maintenance therapy
in patients with metastatic GC following first-line chemotherapy
(44). In total, 805 patients were randomized after 12 weeks
of induction chemotherapy (FOLFOX or XELOX) to either
avelumab 10 mg/kg every 2 weeks or continuation of first-line
chemotherapy. Patients must have had an ORR of stable disease
or better with first-line chemotherapy prior to randomization.
The study failed to meet its primary endpoint of OS benefit for
avelumab. The median OS was similar between avelumab and
chemotherapy (10.4 vs. 10.8 months, HR 0.91). PFS was also
similar between avelumab and chemotherapy (3.2 vs. 4.4 months,
HR 1.04), as was ORR (13 vs. 14%).
The role of ICI in first-line for GC remains controversial based
on these trial results. Despite KEYNOTE-062 achieving one of
its primary endpoints, to date, there is no regulatory approval
for the use of ICI in the first-line. Results from other first-
line studies such as ATTRACTION-4 and CheckMate-649 are
awaited (45, 46).
Ipilimumab in Gastric Cancer
The role of ipilimumab in switch maintenance after first-
line chemotherapy was tested in a randomized phase II study
(47). Patients with metastatic GC that had achieved at least
stable disease with first-line chemotherapy were randomized
to ipilimumab or continuation of chemotherapy. In total 114
patients were randomized, and the study failed to meet its
primary endpoint of PFS. The median PFS of ipilimumab was
inferior to chemotherapy (2.9 vs. 4.9 months, HR 1.44), while OS
was similar (12.7 vs. 12.1 months).
CheckMate-032 was a study that included metastatic GC that
had progressed on at least one line of treatment (48). Patients
were randomized to one of three arms: i.v. nivolumab 3 mg/kg
every 2 weeks (NIVO3), nivolumab 1 mg/kg + ipilimumab 3
mg/kg every 3 weeks for 4 cycles (NIVO1 + IPI3) or nivolumab
3 mg/kg + ipilimumab 1 mg/kg every 3 weeks for 4 cycles
(NIVO3 + IPI1). NIVO1 + IPI3 and NIVO3 + IPI1 regimens
continued with nivolumab 3 mg/kg every 2 weeks after the 4
cycles of combination therapy. In total 160 patients were treated
in the study. ORR was 12% (NIVO3), 24% (NIVO1 + IPI3), and
8% (NIVO3 + IPI1), respectively. Median PFS was 1.4 months
(NIVO3), 1.4 months (NIVO1 + IPI3), and 1.6 months (NIVO3
+ IPI1). The median OS was 6.2 months (NIVO3), 6.9 months
(NIVO1 + IPI3), and 4.8 months (NIVO3 + IPI1). There is no
regulatory approval for the use of ipilimumab in GEC to date.
BIOMARKERS OF IMMUNE CHECKPOINT
INHIBITION IN METASTATIC
GASTROESOPHAGEAL CANCER
PD-L1 Immunohistochemistry
Early development of PD-L1 IHC was conducted in lung cancer.
Trials of various anti-PD-1/anti-PD-L1 antibodies incorporated
different methods and techniques of PD-L1 IHC measurement
for correlative biomarker development (49). Based on these trial
results, different monoclonal antibodies and platforms such as
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TABLE 3 | Results of major pembrolizumab trials based on CPS score.
Name of trial Line of Rx CPS prevalence OS (months) PFS (months) ORR (%) References
≥1 ≥10 0 ≥1 ≥10 0 ≥1 ≥10 0 ≥1 ≥10
KEYNOTE-059 ≥3 57% NA 4.9 5.8 NA NA NA NA 6 16 NA (36)
KEYNOTE-061 2 66% 18% 4.8 9.1 10.4 NA 1.5 NA 2 16 9 (25)
KEYNOTE-062
(Pembro)
1 All 36%* NA 10.6 17.4 NA 2.0 2.9 NA 15 25 (28)
KEYNOTE-062
(Pembro + chemo)
1 All 36%* NA 12.5 12.3 NA 6.9 5.7 NA 49 53 (28)
KEYNOTE-181
(EC)
2 NR 35% 7.1+ 9.3 2.1+ 2.6 13+ 22 (15)
KEYNOTE-180
(EC)
≥3 NR 48% NR 6.3 NR 2.0 NR 14 (39)
*this is the prevalence of CPS ≥ 10 within this trial, which is a biomarker selected population of CPS ≥ 1.
+this trial did not differentiate between CPS 0, and CPS ≥ 1, and the survival/response rates reported here is for the entire trial population (regardless of CPS score).
Pembro, pembrolizumab; chemo, chemotherapy; EC, esophageal carcinoma; NA, not applicable; NR, not reported.
the PD-L1 22C3 pharmDx assay (22C3), 28-8 pharmDx assay
(28-8), SP263 assay (SP263) and SP142 assay (SP142) have
been approved as companion/complementary diagnostics for
nivolumab, pembrolizumab and atezolizumab for lung cancer
(30). The predictive value of PD-L1 IHC to ICI has been variable
across trials. In GC, CPS ≥ 1 occurs in more than half the
patients, while TPS ≥ 1% occurs only in 12.5% of patients (32).
Initial trials of GC did not select for patients based on PD-
L1 status, but retrospective post-hoc analyses were performed
in these trials to correlate CPS score with response rates and
survival. In lung cancer, trials have studied the efficacy of ICI
at different TPS dichotomies (e.g. ≥50 vs. <50% and ≥1 vs.
<1%) (50). In GEC, CPS ≥ 1 and CPS ≥ 10 scores have
been explored as important cut-offs to subclassify patients and
these levels have been studied in greatest depth in clinical trials
using pembrolizumab.
Analysis of Major Pembrolizumab GEC Trials Based
on CPS Score
In the KEYNOTE-059 study, of the 259 patients included, 57%
had a PD-L1 CPS ≥ 1 (51). Patients that were CPS ≥ 1 had
a significantly higher ORR compared to CPS 0 (16 vs. 6%).
However, in both CPS 0 and CPS ≥ 1 subgroups, 3 complete
responses (CR) were detected, and median OS was similar
between both groups (5.8 vs. 4.9 months) (Table 3). In the
KEYNOTE-061 study, the original trial design did not preselect
patients based on CPS score (25). After 489 patients (out of 983 in
total screened) were enrolled, the independent data monitoring
committee recommended that only patients with CPS ≥ 1 were
included in the study. The co-primary end points were specified
to analyze OS and PFS in the CPS ≥ 1 population of the trial.
Of the 592 patients randomized in the study, 395 were CPS ≥ 1.
Pembrolizumab did not improve OS in the CPS ≥ 1 population
(9.1 vs. 8.3 months, HR 0.82). In post-hoc unplanned analysis,
patients with CPS≥ 10 had an improvedOSwith pembrolizumab
compared to paclitaxel (10.4 vs. 8 months) (Table 3). Although
not reported with statistical analyses, inspection of the survival
curves of the CPS < 1 population in KEYNOTE-061 suggests
detriment for patients treated with pembrolizumab compared
to paclitaxel.
In the KEYNOTE-062 study, based on results from earlier
KEYNOTE studies, patients were restricted only to the CPS ≥ 1
population (28). In unplanned, post-hoc analysis, pembrolizumab
had significantly improved survival compared to chemotherapy
in the CPS ≥ 10 subgroup (17.4 vs. 10.8 months). In the
pembrolizumab + chemotherapy arm, similar benefit was not
demonstrated. In the CPS ≥ 10 subgroup, there was no
improvement in survival for pembrolizumab and chemotherapy
compared to chemotherapy alone (12.3 vs. 10.8 months)
(Table 3).
In the EC study KEYNOTE 181, patients were not preselected
for esophageal tumor subtype or CPS score. Based on the
results of the KEYNOTE-061 study, the trial had a pre-
specified co-primary endpoint to study the CPS ≥ 10 population
independently (15). In this study, 35% of tumors were CPS ≥ 10
and 64% were ESCC. Survival was significantly higher in the CPS
≥ 10 population for pembrolizumab vs. chemotherapy (9.3 vs. 6.7
months, HR 0.69) (Table 3).
PD-L1 as a Biomarker in Nivolumab and
Avelumab Trials
In the ATTRACTION-2 study of nivolumab in third-line
metastatic GC patients, PD-L1 IHC was measured using the 28-8
assay, and defined as positive if≥1% of tumor cells demonstrated
staining (approximately equivalent to TPS ≥ 1%) (35). PD-L1
results were not mandated in the inclusion and only 192 of
493 (39%) had IHC results available. Based on this assay, and
definition of PD-L1 positive, only 26 (14%) of patients were
defined as PD-L1 positive. In PD-L1 positive tumors median
OS was 5.2 and 3.8 months for nivolumab and placebo (HR
0.5), while in the PD-L1 negative tumors median OS was 6.1
and 4.2 months for nivolumab and placebo, respectively (HR
0.72). Given the current understanding of the need to measure
immune cell expression of PD-L1 to have amore reliable measure
of PD-L1 expression in GC (i.e., measuring CPS instead of
TPS), these results must be interpreted with caution and are
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TABLE 4 | Major GEC ICI trials.
Name of trial Tumor
subtype
Line of
Rx
PD-L1 IHC
selection
PD-L1 IHC
stratification
References
ATTRACION-2 GC ≥3 No No (35)
KEYNOTE-059
Cohort 1
GC ≥3 No NA (non
randomized)
(36)
JAVELIN-300 GC ≥3 No No (23)
KEYNOTE-061 GC 2 No (first 83%)
CPS ≥ 1
(last 17%)
Yes (CPS ≥ 1) (25)
KEYNOTE-062 GC 1 CPS ≥ 1 No (28)
JAVELIN-100 GC 1 No No (28)
KEYNOTE-181 EC 2 No No (15)
ATTRACTION-3 ESCC 2 No No (41)
KEYNOTE-180 EC ≥3 No NA (non
randomized)
(39)
unlikely to be clinically relevant. In ATTRACTION-3, similar
to ATTRACTION-2, PD-L1 IHC was measured using the 28-8
assay, in tumor cells only (41). ATTRACTION-3 was restricted
only to patients with ESCC, and approximately half the patients
had a PD-L1 expression ≥ 1 and 30% of tumors had PD-L1
expression≥ 10%.MedianOS in the PD-L1< 1% population was
10.9 vs. 9.3 months (HR 0.84) for nivolumab and chemotherapy,
respectively. In the PD-L1 ≥ 1% population, median OS was
10.9 vs. 8.1 months (HR 0.69) for nivolumab and chemotherapy,
respectively, with no significant interaction between PD-L1 status
and treatment. However, the magnitude of benefit does appear
higher in the PD-L1 ≥ 1% population compared to the PD-L1
negative group.
In the JAVELIN-300 Gastric Cancer study of avelumab, PD-
L1 IHC was performed using the 73-10 pharmDx assay (23).
PD-L1 status was defined as positive or negative based on the
expression of at least ≥1% on tumor cells only (approximately
equivalent to TPS≥1%). In total, 23% was PD-L1 positive. There
was no difference in OS between the PD-L1 positive and negative
subgroups (4.0 vs. 4.6 months) or PFS (1.4 vs. 1.4 months), and
consistently poorer than chemotherapy (PFS 2.7 months). In the
JAVELIN-100 Gastric Cancer study, samples were tested for PD-
L1 status using the 73-10 pharmDx assay and the 22C3 assay
(44). With the 73-10 assay (≥1% on tumor cells only) 12% of
patients were defined as PD-L1 positive, and with the 22C3 assay
(CPS ≥1), 64% were defined as PD-L1 positive. Using the 73-
10 assay, the PD-L1 positive population did not have a survival
benefit for avelumab vs chemotherapy (16 vs. 18 months, HR
1.13). However, using the 22C3 assay, the CPS ≥1 population
had a survival benefit for avelumab vs chemotherapy (15 vs. 12
months, HR 0.72).
From these trial results (Table 4), PD-L1 IHC measured using
the 22C3 assay to calculate CPS score appears to have the best
sensitivity to predict for benefit from ICI. GEC tumors with
higher CPS scores tend to have higher responses and survival
when treated with ICI. However, the relationship between CPS
score and benefit is not linear. Rather, there appears to be a cut-off
level, above which benefit occurs. This cut-off is suggested at CPS
≥1 for third-line and CPS ≥10 in first-line. Of note however,
are the occurrences of responses (including CR) and prolonged
survival of patients with CPS 0 (albiet at lower rates compared
to higher CPS scores). This suggests that PD-L1 IHC as a stand-
alone biomarker to predict for ICI benefit may be insufficient.
Microsatellite Instability, Mismatch Repair
Deficiency and Tumor Mutational Burden
The adaptive immune system has the ability to recognize somatic
mutations that occur in tumors. It is also well-established that
tumor types with high levels of somatic mutations such as
melanoma and lung cancer are among the most responsive to
ICI (52). Mismatch repair protein (MMR) deficiency occurs in
several tumor types including gastrointestinal colorectal, gastric,
pancreaticobiliary, small intestine, endometrial, prostate, and
ovarian cancer (53). MMR deficiency occurs through mutations
in genes that recognize and correct errors in mismatched
nucleotides (MLH1, MSH2, MSH6, and PMS2) or through
methylation-induced gene silencing of the promoter of MLH1.
Germline mutations in MMR proteins are associated with Lynch
syndrome, although a majority of MMR deficient tumors are
sporadic and occur through MLH1 promoter methylation. The
inability of the MMR proteins to function normally leads to an
accumulation of errors in DNA microsatellite regions, resulting
in microsatellite instability (MSI). MSI high (MSI-H) tumors
tend to have several-fold higher levels of somatic mutations,
and express larger numbers of predicted neoantigens (54). MSI-
H tumors have demonstrated high response rates to anti-PD-
1 therapy (pembrolizumab and nivolumab), with ORR > 50%
(54, 55). Based on these findings, the FDA granted its first
tissue agnostic approval for pembrolizumab for treatment of
MSI-H tumors across any unresectable/metastatic solid tumor
that had progressed following prior treatment (56). MMR
deficiency can be detected either through demonstrating the loss
of MMR proteins on IHC (deficient MMR, dMMR) or measuring
microsatellite instability by performing PCR on prespecified
microsatellite markers (MSI-H) or by enumerating known MSI
loci using targeted deep next generation sequencing (MSI-
NGS) (57).
In GC, MMR deficiency occurs in ∼8% of early GC (stage I
to stage III) and 4% in metastatic GC (54, 58). MMR deficiency
occurs rarely in EC (<1%), and most EC classified as MSI-
H are EAC within the GEJ areas (14). In the original basket
studies of MMR deficient tumors with pembrolizumab, only
a few GC cases were included. In KEYNOTE-059, 7 patients
(4%) were MSI-H, and 4 had an objective response (57%)
(51). In a phase II study of advanced GC conducted in South
Korea, 61 patients with advanced GC that had progressed on at
least one prior line of treatment were treated with single agent
pembrolizumab and tumor tissues from the patients obtained
prior to ICI treatment were subjected to integrated molecular
analysis (59). In this study, 7 patients were MSI-H (11%)
of which 6 demonstrated deep and durable responses (85%).
In KEYNOTE-061, 27 patients were MSI-H, and 15 of these
were randomized to the pembrolizumab arm (25). Median OS
was not reached (and significantly higher) for those MSI-H
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patients treated with pembrolizumab (vs 8months for paclitaxel).
Similarly, ORR was higher at 47% (vs 17% for paclitaxel). In the
KEYNOTE-062 study, 50 patients were found to be MSI-H, and
in these, the median OS was not reached in the pembrolizumab
arm and the pembrolizumab + chemotherapy arm (60). Median
PFS was 11.2 months in the pembrolizumab arm and not
reached in the pembrolizumab + chemotherapy arm. ORR was
also significantly higher (57% for pembrolizumab and 65% for
pembrolizumab+ chemotherapy).
Methods have been developed to quantify the number of
somatic mutations and reported as tumor mutational burden
(TMB). MMR deficiency is only one of the several causes of
high TMB. Mutations in several other genes such a POLE and
POLD1 have also been associated with high TMB (61). High
TMB has also been associated with smoking-related cancers such
as lung cancer and head and neck cancers, and UV-associated
cancers such as melanoma (62). TMB has been traditionally
measured using whole exome sequencing (WES), but performing
WES in routine clinical practice is difficult. More recently,
TMB has been determined reliably using contemporary next-
generation sequencing (NGS) panels (63). Results of TMB are
often reported as mutations/megabase (mut/Mb) (64). Various
methods have been developed to report NGS panel based TMB.
However, as the different NGS platforms have variations in
sequencing technique and bioinformatic pipelines, there is a
lack of harmonization in the quantification of TMB. Currently,
there is debate and controversy on the predictive cut-off level
to define high TMB across platforms (65). In lung, bladder and
head and neck cancers, >200 somatic mutations detected by
WES predicts consistently for response to ICI. However, the
appropriate thresholds for other tumor types have not been
established (66). There are clinical trials on-going assessing the
role of high TMB in predicting for ICI benefit (CheckMate 848,
NCT03668119 and TELMA, NCT03836066).
In GC, ∼8% of tumors have high TMB, defined as >17
mut/MB in this study (53). However, GEJ tumors were found
FIGURE 2 | Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. PD-L1 expression can be measured in the form of Combined Positive Score
(CPS) has been shown to predict response to anti-PD1 or anti-PD-L1 therapies (1). Microsatellite Instability (MSI) leads to a large number of somatic mutations and
production of neoantigens. MSI is one of the most common causes of high Tumor Mutational Burden (TMB) (2). EBV associated Gastric Cancer (EBVaGC) has been
postulated to be sensitive to ICI due to high intra-tumoral immune infiltration and expression of PD-L1 and PD-L2 (3). Various gene signatures have been developed to
identify genes that can predict response to ICI (4). Combination of HER-2 and anti-PD1 therapy enhance antibody-dependent cellular cytotoxicity leading to improved
outcomes with ICI (5).
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to only have a 3% prevalence of high TMB. Of the 8% of
GCs that were high TMB, a majority of them were driven by
MSI-H. Amongst microsatellite stable (MSS) tumors, only 1.7%
of GC was found to have high TMB. In comparison, 3.5%
of MSS ESCC had high TMB. In the phase II South Korean
study of pembrolizumab, high TMB was defined as >400 non-
synonymous single nucleotide variants (SNVs) in WES (59). Of
the 61 tumors in total, 8 had high TMB (13%), of which 6 were
MSI-H, one MSS and one EBV. ORR in this cohort of high TMB
was 89%. In the moderate TMB group (100–400 SNVs), ORR
was 20%, while in the low TMB group ORR was only 7%. In a
phase I study of toripalimib, an anti-PD-1 antibody, metastatic
GC patients with high TMB (> 20 mut/Mb) (20%) had a better
response compared to low TMB (33 vs. 7%) and survival (15 vs. 4
months, HR 0.48) (67, 68).
From these studies, it is observed that there is only marginal
overlap between MSI-H, TMB and PD-L1 expression. There are
MSI-H tumors that have low TMB, and there are high TMB
tumors which have low PD-L1 expression. Responses to ICI
also do not fully correlate with any of these biomarkers, with
responses occurring in CPS 0 populations and lack of response
seen in patients with MSI-H and high TMB. Recent studies in
MSI-H tumors have shown that the extent of response to ICI is
associated with the specific accumulation of insertion-deletion
mutations (69). Studies to better understand these biomarkers
along with the development of other novel biomarkers are
currently being pursued (Figure 2).
Epstein-Barr Virus Positive Tumors and
Sensitivity to ICI
The TCGA classification of GC identifies EBV associated gastric
cancers (EBVaGC) as a unique subtype (13). EBVaGC are
characterized by high intra-tumoral immune infiltration, and
high transcriptomic expression of PD-L1 and PD-L2. It was
postulated that EBVaGC are likely to be sensitive to ICI. The
prevalence of EBVaGC in the TCGA was reported at 9%,
however this study comprised predominantly of non-metastatic,
resectable GC. EBVaGC tend to have a good prognosis, with
low rates of nodal metastases and recurrence. The prevalence
of EBVaGC in metastatic GC is likely lower than 9%, and few
reports of ICI treatment of EBVaGC exist. Nevertheless, in the
phase II South Korean study of pembrolizumab, six EBVaGC
were included and all of six achieved a partial response (PR) to
treatment, with a median duration of response of 8.5 months
(59). In the phase I study of toripalimab, four EBVaGC were
included and only one attained a PR. Of interest, of the four, only
one was PD-L1 positive (the responder), while the other three
were PD-L1 negative (67). Up to a third of EBVaGC are known
to have low expression of PD-L1 and immune infiltration (70).
However, given the biological rationale and clinical responses to
ICI, it is reasonable to consider treating metastatic EBVaGC with
single agent ICI.
Immune Gene Signatures
Study of the interaction between the tumor and immune
microenvironment has shown distinct classes of the type, location
and density of immune cells within the tumor, with correlation to
prognosis (71). The analysis of various immune related factors
within the tumor, such as density, nature, distribution, and
function is described as the “immune contexture” (72). Recently,
four classes of tumors have been proposed based on the immune
contexture (73). “Hot immune tumors” have high levels of
cytotoxic T-cell infiltration, activation of immune checkpoints
and impaired T-cell function. “Altered-immunosuppressed
tumors” have some cytotoxic T-cell infiltration, but at low levels,
presence of immunosuppressive Tregs and myeloid derived
suppressor cells, and other inhibitory mediators such as TGFβ,
IL-10, and VEGF. “Altered-excluded tumors” have no T-cell
infiltration at the tumor bed, but presence of T-cells at the tumor
invasive margins, epigenetic modifications within the tumor
microenvironment and aberrant tumor stroma and vasculature.
“Cold immune tumors” have absence of T-cells within the
tumor and at the invasive margins, poor T-cell priming and
resistance to T-cell mediated tumor kill. The presence of T-cells
along with other factors such as interferon-γ (IFNγ), perforin
and granzymes have been associated with immune functional
orientation (74). The expression of various immune related
genes has been developed into inflammation and immune gene
signatures, which have been shown to have prognostic benefit
(75–77). The predictive value of these signatures to response
to ICI has been studied in the context of lung cancer and
melanoma, although no signatures have been developed bespoke
to GEC (78). Two of the more evolved signatures include the
IFNγ-related inflammatory signature (79) and an inflammatory
gene signature (80). In KEYNOTE-059, the IFNγ signature
score was higher in responders compared to non-responders
(51). CheckMate-032 was a phase I/II study of nivolumab with
or without ipilimumab in patients with metastatic GC. In a
biomarker analysis of CheckMate-032, various immune gene
signatures were analyzed to predict for response to ICI (81). Of
all the immune signatures tested, a 4 gene panel (PD-L1, CD8A,
LAG3, STAT1) appeared to predict best for response in this small
cohort of 40 patients. KEYNOTE-028 was a phase IB trial of
pembrolizumab in patients with 20 different tumor types. In the
esophageal cohort, 23 patients were enrolled, and a 6 gene IFNγ
signature was tested, and showed a trend toward predicting for
response to ICI (34). The role of immune gene signatures in
predicting benefit from ICI in GEC continues to evolve and has
not been incorporated into clinical practice.
HER2
Overexpression of HER2 in metastatic GC occurs in ∼20%
of tumors and the first-line management of this subtype of
GC is trastuzumab in combination with 5-FU and platinum
chemotherapy (12). A group of investigators hypothesized that
the combination of PD-1 and HER2 inhibition would lead
to activation of T-cells and ameliorate antibody-dependent
cellular cytotoxicity, leading to increase in response. Based on
this hypothesis, a phase II trial of induction pembrolizumab
and trastuzumab followed by 5FU/platinum/trastuzumab and
pembrolizumab was conducted in patients with untreated
metastatic HER2 positive GC (82). In total 35 patients were
enrolled in the study, and 87% of patients had an objective
response to treatment. Median PFS was 11.4 months and median
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OS was not reached at the time of reporting of the study. Based
on these impressive results, a randomized phase III study of
chemotherapy/trastuzumab +/– pembrolizumab (KEYNOTE-
811) has commenced enrollment (83).
Epigenetic Biomarkers
Epigenetic alterations have been investigated as predictive
biomarkers of therapy in GEC. DNA methylation signatures
have been developed to predict for chemotherapy benefit in
GEC (84). In lung cancer, a DNA methylation signature was
developed to predict for ICI response and validated in a separate
cohort. Methylation of FOXP1 was found to be predictive of ICI
response (85). In GC, somatic epigenetic promoter alterations
have been described to be involved in tumor immune editing.
By altering the transcription start sites of high-affinity major
histocompatibility complex class I binding GC peptides, loss of
the immunogenic N-terminal peptide leads to immune evasion
(86). By quantifying the utilization of the alternate promoters to
generate modified isoforms, it was hypothesized that alternate
promoter utilization burden could predict for response to ICI.
In two separate cohorts of ICI treated GC (including the phase II
South Korean study), the alternate promoter utilization burden
predicted for tumors that were resistant to immunotherapy (87).
These findings suggest that alternate promoter utilization burden
may be a negative predictive biomarker for ICI.
FUTURE DIRECTION
The landscape of immunotherapy is rapidly evolving, with
the highest number of clinical trials and studies ever being
conducted in this field. Multiple combinations of ICI with
chemotherapy, targeted therapy and novel agents including
second generation ICI continue to be tested. In the targeted
therapy era, identification of driver genomic mutations and
amplifications followed by blocking these drivers with drugs
led to the development of relatively easy-to-test and implement
biomarkers (88). However, in the immunotherapy era, there is
unlikely to be a single biomarker to identify most patients that
benefit from ICI. The interaction of the immune system with
the tumor microenvironment, microbiome and epigenome is
currently being studied at great depth and insights in these areas
are likely to reveal a more complex, but deeper understanding
of ICI mechanisms of response and resistance (89). It is also
likely that biomarkers developed for PD-1 axis agents may not
be applicable to other novel checkpoint inhibitors.
The deep and durable responses that occur with ICIs are
unique to this class of drugs. Advanced tumors almost invariably
develop resistance to chemotherapy and targeted therapy agents,
thus rendering the intent of treatment as palliative when these
are administered in the metastatic setting. However, there are
now strong data emerging from patients with advanced solid
cancers treated with ICI that have achieved 5-year survival, the
bench mark for curative intent cancer treatment modalities (90).
However, these dramatic responses occur only in a minority of
patients with solid tumors (91). The negative trials that have
played out in GEC are a strong reminder to the oncology
community of this fact. Most of the biomarkers that have been
developed for immunotherapy in GEC aim to identify tumors
that are more likely to benefit from treatment. However, the
remote promise of durable response has led to both patients
and clinicians demanding for treatment with ICI. Perhaps,
in this treatment landscape, the development of a negative
predictive biomarker would be beneficial. One of the best
examples of a negative predictive biomarker is the use of RAS
mutations to predict for lack of benefit of anti-EGFR therapy
in colorectal cancer (92). Similarly, for immunotherapy, it
would be beneficial if immunotherapy-resistant tumors could be
identified and excluded from ICI and considered for alternative
therapeutic options. Given the lack of a single unified predictive
biomarker for immunotherapy currently, the development of
a composite biomarker could be considered, including positive
predictive biomarkers such as PD-L1, MSI, TMB, HER2, and
EBV status, as well as incorporating novel negative predictive
biomarkers. Due to tissue considerations for processing various
components of the composite biomarker (which may include
IHC, genomic sequencing/profiling and fluorescent in-situ
hybridization), industry and academic partners will need to work
closely to evaluate the predictive robustness of such a biomarker
in prospective clinical trials.
Immunotherapy will continue to sculpt the landscape of
GEC in the coming years, and with further advances in
precision oncology through the development of robust predictive
biomarkers, optimal, and bespoke patient treatment strategies
will emerge.
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